# Safety Study of Pyridostigmine in Heart Failure

> **NCT01415921** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 33 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Pyridostigmine Bromide

## Key facts

- **NCT ID:** NCT01415921
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415921, "Safety Study of Pyridostigmine in Heart Failure". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01415921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*